Birgi Mefar and Sanofi Turkey have partnered for a new technology transfer and local production project.
Within the scope of the cooperation, Sanofi's antibiotic product, which reached a turnover of TL 22 million in the Turkish market, will be brought into domestic production with two years of work and will be exported to nearly 40 countries. This investment, worth three million euros, will add more than 500 million TL to Turkey in the period 2020-2026.
BirgiMefar Group CEO Faik Somer said that explained that they had agreed with Sanofi for this production project, which requires a special technology and infrastructure, and said that the production that Sanofi has so far carried out in Rome, the capital of Italy, within the scope of the cooperation, will be moved to Turkey with an investment of 3 million euros.
Birgi Mefar group's half-century-old know-how, infrastructure and experienced staff and its ability to produce sterile products at World Quality Standards have achieved the position of a preferred company for local and foreign projects.
Mefar Pharmaceuticals aims to become a fully equipped subcontractor pharmaceutical manufacturing facility where the selected products of both domestic and global companies are produced for export to EU and MENA countries in the process of starting with localization projects. In this respect, we are proud to be one step closer to this goal in the framework of our cooperation with Sanofi company today.
BirgiMefar Group CEO Faik Somer said that with Sanofi , we believe will continue to grow and continue our cooperation for many years, with this localization project , both company will provide a very valuable contribution to the Turkish pharmaceutical industry. 31.07.2019